Clinical-stage · Vascular medicine
When the vasculature fails, critical illness accelerates.
Vasomune is developing Pegevongitide — AV-001 — a first-in-class investigational therapy designed to activate Tie2 and help restore vascular stability in diseases driven by vascular leak.
The story in one sentence
When infection or injury turns the body’s vascular response against itself, AV-001 is designed to help restore control.
- 1TriggerInjury or infection
- 2BreakdownVascular leak + inflammation
- 3RiskEdema + organ dysfunction
- 4InterventionTie2 activation
- 5Outcome goalBarrier defence restored
Lead asset
Pegevongitide (AV-001)
A first-in-class, fully synthetic PEGylated peptide that activates the Tie2 receptor — a key regulator of endothelial stability and barrier defence.
MechanismFirst-in-class Tie2 activator
DevelopmentPhase 2a clinical study
RegulatoryUS FDA Fast Track Designation
Broader vascular potential
One mechanism. Many diseases driven by vascular leak.
AV-001 begins with a focused lead program in pneumonia and ARDS — supported by biology that may extend across critical illness.
Explore the pipelineSelect a condition to see how it connects to vascular leak.
Lead program · Phase 2a
Pneumonia & ARDS
Severe lung infection can make lung blood vessels leak, flooding the air spaces. This vascular leak is the focus of AV-001’s lead clinical program.